China Resources Pharmaceutical Could Outperform Sinopharm's Growth -- Market Talk

Dow Jones

Aug 27

0222 GMT - China Resources Pharmaceutical could grow faster than peer Sinopharm, driven by the former's traditional Chinese medicine growth likely outpacing its medical distribution business, says Morningstar's Yurou Zheng in a note. Both companies are likely to be hindered by industry developments such as prices being squeezed by tight public spending budgets and competition from e-commerce companies, he says. "We don't expect either to be able to add higher value-added medicines to their distribution business that quickly to shore up profitability," he adds. Morningstar maintains its fair-value estimates on Sinopharm and CR Pharma at HK$24.60 and HK$5.80, respectively. Sinopharm last traded at HK$19.42; CR Pharma was last at HK$5.13. (megan.cheah@wsj.com)

(END) Dow Jones Newswires

August 26, 2025 22:22 ET (02:22 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2562976045"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562976045\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562976045?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-27 10:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562976045","market":"sg","top_or_hot":-1,"title":"China Resources Pharmaceutical Could Outperform Sinopharm's Growth -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0222 GMT - China Resources Pharmaceutical could grow faster than peer Sinopharm, driven by the former's traditional Chinese medicine growth likely outpacing its medical distribution business, says Morningstar's Yurou Zheng in a note. Both companies are likely to be hindered by industry developments such as prices being squeezed by tight public spending budgets and competition from e-commerce companies, he says. \"We don't expect either to be able to add higher value-added medicines to their distribution business that quickly to shore up profitability,\" he adds. Morningstar maintains its fair-value estimates on Sinopharm and CR Pharma at HK$24.60 and HK$5.80, respectively. Sinopharm last traded at HK$19.42; CR Pharma was last at HK$5.13. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 26, 2025 22:22 ET (02:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Resources Pharmaceutical Could Outperform Sinopharm's Growth -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Resources Pharmaceutical Could Outperform Sinopharm's Growth -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-27 10:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0222 GMT - China Resources Pharmaceutical could grow faster than peer Sinopharm, driven by the former's traditional Chinese medicine growth likely outpacing its medical distribution business, says Morningstar's Yurou Zheng in a note. Both companies are likely to be hindered by industry developments such as prices being squeezed by tight public spending budgets and competition from e-commerce companies, he says. \"We don't expect either to be able to add higher value-added medicines to their distribution business that quickly to shore up profitability,\" he adds. Morningstar maintains its fair-value estimates on Sinopharm and CR Pharma at HK$24.60 and HK$5.80, respectively. Sinopharm last traded at HK$19.42; CR Pharma was last at HK$5.13. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 26, 2025 22:22 ET (02:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2562976045","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562976045","pubTimestamp":1756261320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0222 GMT - China Resources Pharmaceutical could grow faster than peer Sinopharm, driven by the former's traditional Chinese medicine growth likely outpacing its medical distribution business, says Morningstar's Yurou Zheng in a note. Both companies are likely to be hindered by industry developments such as prices being squeezed by tight public spending budgets and competition from e-commerce companies, he says. \"We don't expect either to be able to add higher value-added medicines to their distribution business that quickly to shore up profitability,\" he adds. Morningstar maintains its fair-value estimates on Sinopharm and CR Pharma at HK$24.60 and HK$5.80, respectively. Sinopharm last traded at HK$19.42; CR Pharma was last at HK$5.13. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药","SHTDY":"国药控股ADR","01099":"国药控股"},"translate_title":"华润医药可能跑赢国药控股——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1,"03320":0.9,"SHTDY":0.9},"content_text":"0222 GMT - China Resources Pharmaceutical could grow faster than peer Sinopharm, driven by the former's traditional Chinese medicine growth likely outpacing its medical distribution business, says Morningstar's Yurou Zheng in a note. Both companies are likely to be hindered by industry developments such as prices being squeezed by tight public spending budgets and competition from e-commerce companies, he says. \"We don't expect either to be able to add higher value-added medicines to their distribution business that quickly to shore up profitability,\" he adds. Morningstar maintains its fair-value estimates on Sinopharm and CR Pharma at HK$24.60 and HK$5.80, respectively. Sinopharm last traded at HK$19.42; CR Pharma was last at HK$5.13. (megan.cheah@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 26, 2025 22:22 ET (02:22 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}